Compare Medpace Holdings Inc (MEDP) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Workiva Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Workiva Inc trades at $73.27 (market cap $4.01B). The key difference: Medpace Holdings Inc is far larger — about 4.2× Workiva Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Workiva Inc for 21 Days on average.
| MEDP | WK | |
|---|---|---|
Market Cap | $16.82B | $4.01B |
Volume | 223,093 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $630.19 | $93.31 |
52-Week Low | $393.42 | $44.31 |
Typical Hold Time | 14 Days | 21 Days |
Enterprise Value | $16.44B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Workiva (WK) trades at $73.20, up 2.33% with bullish technical indicators and strong analyst support. The company shows improving fundamentals with revenue growth from $885M to $966M and a shift from a $26M loss to $47M profit in 2026. Recent product innovations in AI and regulatory platforms highlight business momentum, supported by consistent earnings beats in recent quarters.
Outlook remains positive with 89% analyst buy ratings and $86 consensus target offering 17% upside. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in regulatory technology. The stock's technical strength and fundamental improvement suggest continued growth potential, though investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
